Trial Profile

A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 15 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vosoritide (Primary)
Indications Achondroplasia
Focus Adverse reactions; Therapeutic Use
Sponsors BioMarin Pharmaceutical

Most Recent Events

10 Oct 2024 Planned End Date changed from 1 Dec 2026 to 1 May 2038.
10 Oct 2024 Planned primary completion date changed from 1 Sep 2026 to 1 May 2038.
12 Mar 2024 According to a BioMarin Pharmaceutical media release, the results from this trial will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com